Prostaglandin E and cancer Growth

J. S. Goodwin, G. Husby, R. C. Williams

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations


This paper reviews the evidence linking prostaglandin E (PGE) with the growth of neoplastic tissue. PGE2 is present in high concentrations in many natural and experimentally produced cancers. The immunosuppressive effect of some tumors in mice is due at least in part to a prostaglandin mechanism. The growth of these same tumors can be slowed and in some cases the tumor eliminated by administration of PG synthetase inhibitors. It is not yet clear whether the antitumor properties of these PG synthetase inhibitors are due to their releasing the hostimmune system from the chronic prostaglandin-mediated suppression of the tumor, resulting in an effective immune response to the tumor, or whether another mechanism is responsible. In humans overproduction of PGE2 by macrophages is partly responsible for the depressed PHA response in patients with Hodgkin's disease.

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalCancer Immunology Immunotherapy
Issue number1
StatePublished - Apr 1980
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Prostaglandin E and cancer Growth'. Together they form a unique fingerprint.

Cite this